Onconova Therapeutics (ONTX) Lowered to Hold at ValuEngine

ValuEngine downgraded shares of Onconova Therapeutics (NASDAQ:ONTX) from a buy rating to a hold rating in a research report released on Wednesday, ValuEngine reports.

Other equities analysts have also recently issued reports about the company. HC Wainwright set a $25.00 target price on Onconova Therapeutics and gave the stock a buy rating in a report on Tuesday. Maxim Group reissued a buy rating and issued a $16.00 price target on shares of Onconova Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research lowered Onconova Therapeutics from a buy rating to a hold rating in a research report on Wednesday, January 16th.

ONTX stock traded down $0.35 during midday trading on Wednesday, reaching $3.81. 31,197 shares of the company were exchanged, compared to its average volume of 111,490. Onconova Therapeutics has a one year low of $1.69 and a one year high of $11.17. The stock has a market cap of $22.55 million, a price-to-earnings ratio of -0.76 and a beta of 2.95.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.18). The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.08 million. Onconova Therapeutics had a negative return on equity of 336.39% and a negative net margin of 1,675.33%. Research analysts expect that Onconova Therapeutics will post -2.43 EPS for the current fiscal year.

A hedge fund recently raised its stake in Onconova Therapeutics stock. Dimensional Fund Advisors LP increased its position in Onconova Therapeutics Inc (NASDAQ:ONTX) by 148.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 32,490 shares of the biopharmaceutical company’s stock after acquiring an additional 19,404 shares during the quarter. Dimensional Fund Advisors LP owned about 0.55% of Onconova Therapeutics worth $107,000 as of its most recent SEC filing. 48.05% of the stock is owned by hedge funds and other institutional investors.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.

See Also: Do equity income investments outperform growth and income investments?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.